30 Minutes Without Coffee Is the Price of the Wegovy Pill in Australia

The glass goes on the bedside table the night before. Not a full glass. Half a glass, up to 120 millilitres, because the tablet is swallowed whole first thing in the morning, on a stomach empty for at least eight hours, and then nothing else follows it for half an hour. No coffee. No breakfast. No other pill. The Wegovy pill, registered in Australia on 3 November, asks for that stretch of the morning every day, and the papers that describe it say plainly what happens when the stretch shortens. Less of the dose arrives.

The register entry is short. The Therapeutic Goods Administration recorded Wegovy semaglutide 1.5 mg tablet blister pack, ARTG 522753, on 3 November 2026, and a 25 mg pack, ARTG 522759, on the same date. A Department of Health spokesman said the strengths are 1.5, 4, 9 and 25 mg, and that the indications are consistent with those approved for the injectable Wegovy. Novo Nordisk has said it is working to bring the new treatment option to Australia. Reports have put the arrival before Christmas. The company has not announced a launch date, and it has not announced an Australian price. A figure of 10,000 has circulated in syndicated coverage about a waiting list, without a named list behind it in what was published, so it is not a number this article can stand behind.

Wegovy injections are not on the Pharmaceutical Benefits Scheme. The Pharmaceutical Benefits Advisory Committee recommended a narrow listing on 5 November 2025, for people with established cardiovascular disease and a body mass index of 35 or more, and the sponsor’s documentation was not accepted in February 2026, with a revised proposal before the committee’s November 2026 meeting. The government has committed to a listing, with price negotiation and risk-sharing, which would put a script at $25, or $7.70 on concession. The pill itself has no PBS recommendation of its own. Overseas cash prices, labelled by country because Australia has none yet, run $149 for the 1.5 mg strength, $199 for 4 mg and $299 for 9 and 25 mg per 30 tablets on NovoCare in the United States, and €172.73 to €277.60 per 30 in Germany, where the tablet is unreimbursed. In Australia, Chemist Warehouse listed starter injection pens at $249.99 and the 1.7 and 2.4 mg pens at $369.99 in October 2026. Those are the nearest Australian numbers, and they belong to a different form of the drug.

Only about 1 to 2 percent of an oral dose reaches the bloodstream. Absorption happens mainly in the stomach, helped by salcaprozate sodium, known as SNAC, and food or a large volume of water lowers it, while longer fasting before and after the dose raises it. That is the reason for the morning rule, in the European product information, the fullest dosing document published for the tablet. The same document puts total exposure varying by 166 percent after a single dose and 68 percent at steady state, with 33 percent of that variation within the same person from dose to dose. It warns that absorption is highly variable and may be minimal, and that the absolute amount reaching the blood is low. In one study, taking the tablet with five other tablets cut semaglutide exposure by 34 percent and its peak concentration by 32 percent. Half-life is about a week. Steady state takes four to five weeks, and the drug is still present about seven weeks after the last dose.

One 1.5 mg tablet a day for a month, then 4 mg for a month, then 9 mg, then 25 mg from the fourth month, one tablet a day and never two to reach a higher dose. The top strength, oral semaglutide 25 mg, is the maintenance dose. The leaflet gives that timetable, which the announcement stories skipped. A missed dose is skipped, with the next day’s tablet taken as usual, and the leaflet adds a sentence that reads like a warning to anyone who expected a simpler routine: if the expected response does not arrive, it may be because of how the body absorbed the medicine. Swallow the tablet whole, it says, and do not split, crush or chew it. Waiting less than 30 minutes lowers the absorption of semaglutide. The European summary says the tablet is not recommended for people under 18.

People already injecting can move across, but the document does not promise the move will feel the same. Someone on the weekly 2.4 mg injection can be transitioned to the 25 mg daily tablet starting one week after the last injection, and the summary warns that the effect of switching cannot easily be predicted because the oral form varies more from dose to dose. In type 2 diabetes, where the response is inadequate, it advises considering a switch back to the injection.

OASIS 4 followed 307 adults at 22 sites in four countries for 64 weeks, people with a body mass index of 30 or more, or 27 or more with a weight-related condition, and no diabetes. Counting everyone randomised, whether they kept to the routine or not, weight fell 13.6 percent on the tablet against 2.2 percent on placebo, a gap of 11.4 points, and 76.3 percent lost at least 5 percent of their weight against 31.3 percent on placebo. Counting only those who took the treatment as directed, the fall was 16.6 percent against 2.7 percent, and 34.4 percent lost at least 20 percent. Secondary reporting of the trial put prediabetes returning to normal in 71.1 percent against 33.3 percent, and serious adverse events at 3.9 percent against 8.8 percent. The most common side effects were gastrointestinal, during the dose increases. The 17 percent figure in Australian coverage is the second number, the adherent one, without the first beside it, and without the trial’s name.

Australia is not first. The United States Food and Drug Administration approved the Wegovy pill on 22 December 2025, the first oral GLP-1 for weight management, and it went on sale on 5 January 2026, reaching about two million prescriptions by the week ending 17 April 2026, with about 1.3 million of those in the first quarter and first-quarter pill sales of 2.26 billion Danish kroner, about $354 million, roughly half through self-pay channels. Britain approved it on 11 June 2026 and it went on private sale on 6 July, not funded by the NHS, with a National Institute for Health and Care Excellence assessment still pending. The European Union authorised it on 15 July 2026, and Germany had it on sale on 1 September. Eli Lilly’s rival tablet, Foundayo, approved in the United States in April 2026, carries no food or water restrictions and a missed dose is taken when remembered, with a positive European opinion in October 2026 and a decision pending, and it is not approved in Australia.

The counterfeit risk travelled with the pill in Britain, where the National Pharmacy Association warned about fakes at launch, and the TGA has warned against compounded semaglutide, illegal to make or supply in Australia since 1 October 2024, after accepting a court-enforceable undertaking from a compounding pharmacy over its advertising.

The morning rule is not new, and the people who have lived it were taking a different tablet. Rybelsus, an earlier oral semaglutide for diabetes at lower doses, has carried the same instructions for years, and its users describe a routine that bends around coffee, walks and other medicines rather than absorbing them. One Reddit poster, u/heckinbeaches, wrote in 2022: “I take Rybelsus first thing in the morning, on an empty stomach, with exactly 4oz of water. I don’t eat or drink anything for another 45 minutes, so I walk 2 miles during that time.” Another, u/cassandralife, wrote in 2024 about a morning when coffee arrived first: “my dear husband had made me some coffee and brought it to me to bed, so I had it without a second thought. A few minutes later I realized I forgot to take it.” She went on to ask whether waiting a couple of hours without food or drink would let her take that day’s dose, a question the leaflet answers only by telling her to skip it. A third, u/Fearless_Bunch_4580, who had switched to Rybelsus after eight months on Ozempic because Ozempic was impossible to get where they live, wrote in January 2025: “you have to take it first thing in the morning and then wait at least 30 minutes before taking any other medication, food or drinks. That’s upset my routine a bit because I have a few medications I need to take in the morning.” They added that they would prefer to be back on Ozempic. Novo Nordisk has presented the Wegovy pill as fitting easily into the morning routine.

The tablets have a three-year shelf life and need no special temperature storage conditions. They are to be protected from light and moisture.